Archangels - Making The Future

Rules of Engagement

Please click for an easy to print version of our Rules of Engagement.

RULES OF ENGAGEMENT - DECEMBER 2009

This note summarises the rules under which opportunities may be offered to members of the Archangels investment syndicate and the procedures adopted for the completion of investments by such members. 

The Archangels investment syndicate (often just called Archangels or Archangel) is comprised of a core group of investors and a larger group of non-core investors.  The syndicate is administered by Archangel Informal Investment Limited (AIIL), which is a not for profit company, and the executive team of this administration company is headed up by John Waddell, CEO.

The provisions of the Financial Services and Markets Act 2000 and the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (together the "FSMA") have been taken into account in framing these rules and procedures.

1.            All new business proposals for investment by members of the Archangels syndicate and requests for further funding from existing investments will be reviewed by John Waddell.

2.            The decision to invest in a proposal and the structure of the deal will be the responsibility of the core investor group, currently consisting of Mike Rutterford, Barry Sealey, Eric Young, Gavin Gemmell and Alastair Salvesen.  Any decision to invest by the core investor group will be unanimous and will give rise to a personal investment by the core investor group members (or their nominees) of at least £100,000 between them.

3.            If the total investment is less than £100,000, the core investor group are likely to cover the investment themselves.  If the total investment exceeds £100,000 then all syndicate members will be offered the opportunity to invest on the same basis as the core investor group.  Minimum investment level for each non-core investor is likely to be £10,000.

4.            Investment opportunities will be circulated by way of email and potential investors have the opportunity to exercise any diligence they wish such as meeting with management teams, requesting full business plans etc.  A presentation to potential investors from Archangels by the management team will normally be organised by AIIL.

5.            Those members who make investments in new business proposals will be charged an administration fee by AIIL of 5% plus VAT of the amount invested up to a maximum of £5,000 per investment.  No fee is charged for further funding rounds.

6.            All members are required to comply with the certification requirements of the FSMA and the terms of the Money Laundering Regulations 2007 (as amended).  All members must also sign an Archangels membership form and a 2 year General Archangels Power of Attorney which is in favour of the directors of AIIL.  The Power of Attorney is used to help administer the investments of each Archangels member in accordance with the instructions of each member.

7.            Equity investments by individual members of Archangels will normally qualify for Enterprise Investment Scheme relief (unless otherwise advised or the nature of the investment is such (eg a loan, which may be convertible into shares) where such relief shall not apply).

8.            The completion of investments will be co-ordinated by our lawyers, normally MBM Commercial and John Waddell, Robert Pattullo or another director of AIIL who will, where required, act as attorney under the General Archangel Power of Attorney for those members of Archangels who plan to invest.

9.            Each member of Archangels acknowledges that a decision to invest is a decision by that member alone and that no responsibility for the consequences of that decision is accepted by AIIL, any member of the core group, John Waddell or any directors of Archangels.

10.          Dissemination of information post investment is the responsibility of the relevant investee company to each Archangels investor.  There will normally be an investment agreement entered into with the company and this agreement will set out the information rights of Archangels members.

11.          Where appropriate, application will be made to the Scottish Enterprise - Scottish Co-Investment Fund for investment of up to 50% of the total required.  Such investment will be on the same terms as apply to individual Archangels members.

 

Latest News

Touch Bionics unveils the new i-LIMB Pulse

05 May 2010
Touch Bionics today announced the launch of the i-LIMB Pulse, an all-new version of the revolutionary i-LIMB Hand, the wordl's first commercially available bionic hand. The i-LIMB Pulse is a significant advance for the i-LIMB product line, with a host of enhancements, including pulsing grip strength, software-enabled grip patterns and robust aluminium features for improved strength.

Touch Bionics wins prestigious Queen's Award for innovation

21 Apr 2010
Touch Bionics, developer of advanced upper-limb bionic technologies, today announced it is a winner of the prestigious Queen's Awards for Enterprise with an award in the Innovation category for 2010. The Queen's Awards for Enterprise are the UK's most prestigious awards for business performance.

Bloxx Delivers Web Filtering Excellence at Wellingborough School

21 Apr 2010
School has immediate access to safe internet surfing with Bloxx Web Filtering. Bloxx today announced that Wellingborough School is providing safe Internet access for around 900 users and achieving superior anonymous proxy detection by using Bloxx's real time Web filtering, powered by its patented Tru-View Technology.

Bloxx helps Yorkshire Building Society keep staff safe online

15 Apr 2010
Bloxx the innovator in Web content filtering, announced on 15th April that Yorkshire Building Society is using Bloxx Web filtering to monitor and report on the Web browsing activity of over 2,000 staff, delivering superior protection from imappropriate or productivity impacting content and minimising network security risks.

New "Penicillin" for the 21st Century

01 Apr 2010
Today MGB Biopharma Limited, a late preclinical stage biopharmaceutical company, has commenced operations in Glasgow, UK to develop and commercialise a new class of antibacterial product: DNA Minor Groove Binders.